cerrar
Tagged with Opinion

An International Approach to Boosting the US Biosimilars Market
Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient…

The Cell & Gene Therapy Market: Coming into Its Own
David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in the cell and gene therapy market for investments…

Tales from the Trenches: One Female Pharma Executive’s…
US industry veteran Sharon Ayd describes her journey to becoming a pharma company board member, the various hurdles still facing female pharma…

Forging a New Path to Commercialization for Cell and Gene…
Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in…

The “CDP” Cure for Common “Rx” Marketing
Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to…

Value Based Care: In Need of More Patient and Physician Voices
Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to…

Europe: Political Complexity Bodes Poorly for Pharma
Aditya Bhattacharji takes a look at the potentially damaging impact of political uncertainty across Europe - including the impending exit of the UK…

The Ongoing Battle to Crack the Alzheimer’s Treatment Dilemma
David H. Crean highlights R&D efforts and ongoing investments in Alzheimer’s disease treatments as we enter the month of June, brain awareness…

Let’s Treat Cannabis Like the Medicine It’s Been For Over…
David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health –…

Chengdu: The First Steps Towards Mutual Insurance In China
Better known for its panda sanctuary and spicy local cuisine, Chengdu could be the first Chinese city to offer mutual health insurance. Eric…

Shooting For the Stars: The Evolution in Outcome-Based Payment…
Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful…

The US Generic Drug Supply Chain: “Standardized,…
Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA.…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here